Paradigm Biopharmaceuticals Plans Major Share and Option Issue to Boost Capital

The latest announcement is out from Paradigm Biopharmaceuticals ( (AU:PAR) ).

Paradigm Biopharmaceuticals has outlined a proposed capital raising involving the issue of 73,684,211 new ordinary fully paid shares and two tranches of 73,684,211 quoted options each, with different exercise prices and expiries. The securities are to be issued via a placement or similar structure, with an expected issue date of 1 May 2026, signaling a significant funding initiative that may impact the company’s capital structure and liquidity for future operations.

The options series include one class expiring in December 2026 or 20 business days after a specified announcement, and another class expiring in April 2029, providing investors with longer-dated leveraged exposure to the company’s equity. This sizable issuance, subject to ASX processes, positions Paradigm to access additional capital over time if options are exercised, potentially supporting pipeline advancement while also introducing dilution considerations for existing shareholders.

The most recent analyst rating on (AU:PAR) stock is a Buy with a A$0.65 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Limited is an Australia-listed biotechnology company focused on developing pharmaceutical therapies, with its ordinary shares traded on the ASX under the code PAR. The company operates in the biopharmaceutical sector, pursuing capital markets activities to support its research, development, and commercial objectives.

YTD Price Performance: -33.82%

Average Trading Volume: 1,214,546

Technical Sentiment Signal: Sell

Current Market Cap: A$101.6M

Find detailed analytics on PAR stock on TipRanks’ Stock Analysis page.